BioSpace News Archive

The AI-powered nonprofit startup Reboot Rx launches the Reboot: COVID-Cancer Project, a free, publicly accessible resource for researchers and physicians to quickly find and review data on COVID-19 and cancer.

Blue Sprig Pediatrics, Inc. announces that it has acquired the assets of the Carmel, CA based Aptitude Habilitation Services.

Surfaces contaminated with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, pose a threat to the safety of healthcare providers, schools, office workers, and essential businesses, who face the risk of contracting COVID-19 in their workplace

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced second quarter 2020 financial results and business updates.

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, announced financial results for the three and six months ended June 30, 2020.

RGX-314 subretinal delivery pivotal program for wet AMD to initiate by end of 2020; positive interim update from Cohorts 4 and 5 at one year in Phase I/IIa trial recently announced

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.

“We achieved record net sales of $15.3 million in the second quarter while maintaining our focus on the science, announcing our 200th research agreement and tenth published human trial on Niagen®,” says ChromaDex CEO Rob Fried.

Acceleron recognized approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) and a $25.0 million regulatory-based milestone from Bristol Myers Squibb

Cutera, Inc., a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, reported financial results for the second quarter ended June 30, 2020.